|
Oct. 17, 2025 |
|
|
Feb. 13, 2026 |
|
|
jRCT2051250132 |
Pharmacokinetic study of STN1014003 ophthalmic solution in healthy male adults |
|
Pharmacokinetic study of STN1014003 ophthalmic solution in healthy male adults |
Sakamoto Kayoko |
||
Santen pharmaceutical co.,ltd |
||
4-20 Ofuka-cho, Kita-ku, Osaka, Japan |
||
+81-6-4802-9341 |
||
clinical@santen.co.jp |
||
Sakamoto Kayoko |
||
Santen pharmaceutical co.,ltd |
||
4-20 Ofuka-cho, Kita-ku, Osaka, Japan |
||
+81-6-4802-9341 |
||
clinical@santen.co.jp |
Complete |
Oct. 16, 2025 |
||
| Nov. 09, 2025 | ||
| 8 | ||
Interventional |
||
single arm study |
||
open(masking not used) |
||
uncontrolled control |
||
single assignment |
||
treatment purpose |
||
Subjects who can comply with scheduled visits and the examination and observation as specified in the clinical study protocol |
||
1)Subjects have a disease and/or abnormal laboratory value which is considered inappropriate from safety evaluation perspective |
||
| 18age old over | ||
| 35age old under | ||
Male |
||
Open angle glaucoma (OAG) or Ocular hypertension (OHT) |
||
STN1014003 ophthalmic solution , 1 drop once daily for 8days |
||
Plasma pharmacokinetics |
||
| Santen pharmaceutical co.,ltd |
| Medical Corporation Heishinkai OPHAC Hospital IRB | |
| 4-1-29 Miyahara Yodogawa-ku, Osaka-shi, Osaka, Japan, Osaka | |
+81-6-6395-9000 |
|
| ophach_irb@heishinkai.com | |
| Approval | |
Oct. 09, 2025 |
No |
|
none |